Lymphoma Clinical Trials in Baltimore

Showing 601-620 of 742 trials

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT01278615

This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Recurrent Adult Diffuse Large Cell Lymphoma

National Cancer Institute (NCI)16 participantsStarted Dec 2010

Chicago, Illinois, United States • Chicago, Illinois, United States • Decatur, Illinois, United States +13 more locations

COMPLETEDNA< 1 mile

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

NCT00080873

RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation. PURPOSE: This randomized clinical trial is studying how well Traumeel® S works in preventing or treating mucositis in young patients who are receiving chemotherapy with or without total-body irradiation before undergoing stem cell transplantation.

Kidney CancerLeukemiaLymphoma+3 more

Children's Oncology Group195 participantsStarted Apr 2004

Birmingham, Alabama, United States • Los Angeles, California, United States • Orange, California, United States +41 more locations

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Lymphoma Trials in Other Cities

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Other Conditions in Baltimore